← Leaderboards
Craig Thomas
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Center For Advancing Translational Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Screening”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,487,925
- David Heimbrook · Leidos Biomedical Research, Inc.$277,323,479
- Richard A Gibbs · Baylor College Of Medicine$249,395,936
- David R. Weir · University Of Michigan At Ann Arbor$236,797,614
- Peter B. Gilbert · Fred Hutchinson Cancer Center$153,633,436
- Ralph Parchment · Leidos Biomedical Research, Inc.$135,017,102
Research focus
ScreeningSmall MoleculeResearch PersonnelTechnologyPhenotypeCollaborationsPharmaceutical PreparationsInnovationEvaluationScientistTherapeutic DevelopmentDisease ModelPlayInhibitor/AntagonistClinical TrialsMalignant NeoplasmsBiologyPropertyCancer TypeEnzymesResearch Clinical TestingKinase InhibitorCombined Modality TherapyLibraries
Grant awards (68)
HTS enabled examination of drug combinations$1,215,806
ZIA · FY2025 · TR · contact PI
Bioactive small molecule development- PKM2 program$455,928
ZIA · FY2025 · TR · contact PI
Bioactive small molecule development- LATS program$455,928
ZIA · FY2025 · TR · contact PI
Bioactive small molecule development- Ketamine metabolite program$455,928
ZIA · FY2025 · TR · contact PI
Disease model design and evaluation$151,976
ZIA · FY2025 · TR · contact PI
Bioactive small molecule development- IRAK-FLT3 program$151,976
ZIA · FY2025 · TR · contact PI
Novel small molecule library development$151,976
ZIA · FY2025 · TR · contact PI
HTS enabled examination of drug combinations$1,881,570
ZIA · FY2024 · TR · contact PI
Bioactive small molecule development$1,881,569
ZIA · FY2024 · TR · contact PI
Disease model design and evaluation$470,392
ZIA · FY2024 · TR · contact PI
Novel small molecule library development$470,392
ZIA · FY2024 · TR · contact PI
HTS enabled examination of drug combinations$1,863,560
ZIA · FY2023 · TR · contact PI
Bioactive small molecule development$1,863,560
ZIA · FY2023 · TR · contact PI
Novel small molecule library development$465,891
ZIA · FY2023 · TR · contact PI
Disease model design and evaluation$465,890
ZIA · FY2023 · TR · contact PI
Development of (R,R)-dehydronorketamine for treatment resistant depression$3,950,053
ZIA · FY2022 · TR · contact PI
HTS enabled examination of drug combinations$567,210
ZIA · FY2022 · TR · contact PI
Novel small molecule library development$465,615
ZIA · FY2022 · TR · contact PI
The development of multikinase inhibitors for the treatment of selected cancers$395,521
ZIA · FY2022 · TR · contact PI
Development of a novel aIIbB3 receptor antagonist for pre-hospital myocardial infarction therapy$315,907
ZIA · FY2022 · TR · contact PI
Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor$310,921
ZIA · FY2022 · TR · contact PI
Development of (R,R)-dehydronorketamine for treatment resistant depression$3,601,077
ZIA · FY2021 · TR · contact PI
HTS enabled examination of drug combinations$352,622
ZIA · FY2021 · TR · contact PI
Development of a novel aIIbB3 receptor antagonist for pre-hospital myocardial infarction therapy$265,962
ZIA · FY2021 · TR · contact PI
Novel small molecule library development$255,063
ZIA · FY2021 · TR · contact PI
Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor$202,542
ZIA · FY2021 · TR · contact PI
The development of multikinase inhibitors for the treatment of selected cancers$187,754
ZIA · FY2021 · TR · contact PI
Development of (R,R)-dehydronorketamine for treatment resistant depression$4,270,523
ZIA · FY2020 · TR · contact PI
Development of novel antimalarial targets and combination therapies to address drug resistance$381,978
ZIA · FY2020 · TR · contact PI
Novel small molecule library development$352,555
ZIA · FY2020 · TR · contact PI
HTS enabled examination of drug combinations$352,210
ZIA · FY2020 · TR · contact PI
Development of a novel aIIbB3 receptor antagonist for pre-hospital myocardial infarction therapy$251,965
ZIA · FY2020 · TR · contact PI
The development of multikinase inhibitors for the treatment of selected cancers$229,521
ZIA · FY2020 · TR · contact PI
Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor$226,921
ZIA · FY2020 · TR · contact PI
Development of (R,R)-dehydronorketamine for treatment resistant depression$3,594,882
ZIA · FY2019 · TR · contact PI
Novel small molecule library development$299,548
ZIA · FY2019 · TR · contact PI
Development of novel antimalarial targets and combination therapies to address drug resistance$295,661
ZIA · FY2019 · TR · contact PI
HTS enabled examination of drug combinations$286,205
ZIA · FY2019 · TR · contact PI
Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor$211,854
ZIA · FY2019 · TR · contact PI
The development of multikinase inhibitors for the treatment of selected cancers$209,554
ZIA · FY2019 · TR · contact PI
Development of a novel aIIbB3 receptor antagonist for pre-hospital myocardial infarction therapy$199,583
ZIA · FY2019 · TR · contact PI
Development of (R,R)-dehydronorketamine for treatment resistant depression$1,888,435
ZIA · FY2018 · TR · contact PI
Novel small molecule library development$247,058
ZIA · FY2018 · TR · contact PI
Development of novel antimalarial targets and combination therapies to address drug resistance$215,526
ZIA · FY2018 · TR · contact PI
HTS enabled examination of drug combinations$190,873
ZIA · FY2018 · TR · contact PI
Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor$186,357
ZIA · FY2018 · TR · contact PI
The development of multikinase inhibitors for the treatment of selected cancers$168,033
ZIA · FY2018 · TR · contact PI
Development of a novel aIIbB3 receptor antagonist for pre-hospital myocardial infarction therapy$125,326
ZIA · FY2018 · TR · contact PI
Development of (R,R)-dehydronorketamine for treatment resistant depression$768,952
ZIA · FY2017 · TR · contact PI
Novel small molecule library development$294,362
ZIA · FY2017 · TR · contact PI
Development of novel antimalarial targets and combination therapies to address drug resistance$235,576
ZIA · FY2017 · TR · contact PI
HTS enabled examination of drug combinations$205,360
ZIA · FY2017 · TR · contact PI
The development of multikinase inhibitors for the treatment of selected cancers$201,563
ZIA · FY2017 · TR · contact PI
Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor$196,357
ZIA · FY2017 · TR · contact PI
Development of a novel aIIbB3 receptor antagonist for pre-hospital myocardial infarction therapy$125,326
ZIA · FY2017 · TR · contact PI
Development of (R,R)-dehydronorketamine for treatment resistant depression$416,173
ZIA · FY2016 · TR · contact PI
Novel small molecule library development$215,281
ZIA · FY2016 · TR · contact PI
Development of novel antimalarial targets and combination therapies to address drug resistance$179,706
ZIA · FY2016 · TR · contact PI
Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor$169,015
ZIA · FY2016 · TR · contact PI
The development of multikinase inhibitors for the treatment of selected cancers$166,843
ZIA · FY2016 · TR · contact PI
HTS enabled examination of drug combinations$147,272
ZIA · FY2016 · TR · contact PI
Development of a novel aIIbB3 receptor antagonist for pre-hospital myocardial infarction therapy$73,681
ZIA · FY2016 · TR · contact PI
Novel small molecule library development$110,000
ZIA · FY2015 · TR · contact PI
The development of multikinase inhibitors for the treatment of selected cancers$85,250
ZIA · FY2015 · TR · contact PI
Development of a novel aIIbB3 receptor antagonist for pre-hospital myocardial infarction therapy$75,296
ZIA · FY2015 · TR · contact PI
Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor$61,360
ZIA · FY2015 · TR · contact PI
Development of (R,R)-dehydronorketamine for treatment resistant depression$57,594
ZIA · FY2015 · TR · contact PI
HTS enabled examination of drug combinations$46,230
ZIA · FY2015 · TR · contact PI